1. Medtech Insight
  2. >>Geography
  3. >>Europe

What Changes To The AI Act Would Benefit Medtech Most?

 
• By Eliza Slawther

With the European Commission’s AI Act now in the final negotiation phase, industry bodies MedTech Europe and COCIR have outlined several areas where the draft text could be altered to optimize the potential of AI in health care.

AI Legislation
• Source: Shutterstock

European trade bodies MedTech Europe and COCIR have co-signed a letter with 11 other health organizations urging EU policymakers to “strongly consider” the impact the Artificial Intelligence (AI) Act proposal will have on the EU health ecosystem while firming up details of the final legislation.

Key Takeaways

Trilogue negotiations between the European Parliament, Commission and Council on the content of the draft AI Act began last month and represent the final opportunity for changes to be agreed to the draft text before the legislation is adopted.

During this process, the three entities will present their own versions of the draft text, and eventually reach a decision on the final unified version.

These discussions may go on for some 12-18 months, depending on how long it takes for an agreement to be reached on the details of the proposal.(Also see "EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, And When?" - Medtech Insight, 7 June, 2023.)

A key priority during these trilogues, the stakeholders say in their letter, is ensuring the AI Act is aligned with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

The NHS England chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 
• By Amanda Maxwell

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

More from Geography

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By Elizabeth Orr

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 
• By Michael McCaughan

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.